BR112016015678A2 - Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso - Google Patents
Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu usoInfo
- Publication number
- BR112016015678A2 BR112016015678A2 BR112016015678A BR112016015678A BR112016015678A2 BR 112016015678 A2 BR112016015678 A2 BR 112016015678A2 BR 112016015678 A BR112016015678 A BR 112016015678A BR 112016015678 A BR112016015678 A BR 112016015678A BR 112016015678 A2 BR112016015678 A2 BR 112016015678A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- ospa
- pharmaceutical composition
- fragments
- mutanted
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000012634 fragment Substances 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010061591 Borrelia infection Diseases 0.000 abstract 3
- 108700006640 OspA Proteins 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
FRAGMENTOS MUTANTES DE OSPA E MÉTODOS E USOS RELACIONADOS AOS MESMOS. A presente invenção refere-se a composições e métodos para a prevenção e tratamento de infecção por Borrelia. Particularmente, a presente invenção refere-se a um polipeptídeo que compreende um fragmento híbrido C-terminal de uma proteína da superfície externa A (OspA), um ácido nucleico que codifica o mesmo, um anticorpo que se liga especificamente ao mesmo, uma composição farmacêutica (particularmente para utilização como um medicamento ou em um método de tratamento ou prevenção de uma infecção por Borrelia) que compreende o polipeptídeo e/ou o ácido nucleico e/ou o anticorpo, um método de tratamento ou prevenção de uma infecção por Borrelia e um método de imunização de um indivíduo.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122023024315-3A BR122023024315A2 (pt) | 2014-01-09 | 2015-01-09 | Polipeptídeo contendo fragmentos mutantes de ospa e composição farmacêutica |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14150682 | 2014-01-09 | ||
| PCT/EP2015/050365 WO2015104396A1 (en) | 2014-01-09 | 2015-01-09 | Mutant fragments of ospa and methods and uses relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016015678A2 true BR112016015678A2 (pt) | 2017-10-03 |
| BR112016015678B1 BR112016015678B1 (pt) | 2024-02-06 |
Family
ID=49917594
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016015678A BR112016015678B1 (pt) | 2014-01-09 | 2015-01-09 | Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica |
| BR122023024315-3A BR122023024315A2 (pt) | 2014-01-09 | 2015-01-09 | Polipeptídeo contendo fragmentos mutantes de ospa e composição farmacêutica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122023024315-3A BR122023024315A2 (pt) | 2014-01-09 | 2015-01-09 | Polipeptídeo contendo fragmentos mutantes de ospa e composição farmacêutica |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9975927B2 (pt) |
| EP (2) | EP3092246B1 (pt) |
| JP (1) | JP6505110B2 (pt) |
| KR (1) | KR102460165B1 (pt) |
| CN (1) | CN105980398B (pt) |
| AU (1) | AU2015205520B2 (pt) |
| BR (2) | BR112016015678B1 (pt) |
| CA (1) | CA2931110A1 (pt) |
| CY (1) | CY1121734T1 (pt) |
| DK (1) | DK3092246T3 (pt) |
| EA (1) | EA034554B1 (pt) |
| ES (1) | ES2740985T3 (pt) |
| HR (1) | HRP20191086T1 (pt) |
| HU (1) | HUE043779T2 (pt) |
| LT (1) | LT3092246T (pt) |
| MX (1) | MX369195B (pt) |
| NZ (1) | NZ721015A (pt) |
| PL (1) | PL3092246T3 (pt) |
| PT (1) | PT3092246T (pt) |
| RS (1) | RS59075B1 (pt) |
| SI (1) | SI3092246T1 (pt) |
| TR (1) | TR201910117T4 (pt) |
| WO (1) | WO2015104396A1 (pt) |
| ZA (1) | ZA201602690B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| ES2740985T3 (es) | 2014-01-09 | 2020-02-07 | Valneva Austria Gmbh | Fragmentos mutantes de OspA y métodos y usos relacionados con los mismos |
| ES2957939T3 (es) | 2017-04-13 | 2024-01-30 | Valneva Austria Gmbh | Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos |
| CN110483624B (zh) * | 2019-08-22 | 2021-02-09 | 中国疾病预防控制中心传染病预防控制所 | 伽氏疏螺旋体OspA蛋白C端肽段及其应用 |
| AU2021254265A1 (en) | 2020-04-09 | 2022-11-03 | Pfizer Inc. | Compositions comprising three OspA fusion proteins for medical use |
| WO2021205017A1 (en) | 2020-04-09 | 2021-10-14 | Valneva Austria Gmbh | Improvements in vaccine formulations for medical use |
| WO2023212520A1 (en) | 2022-04-25 | 2023-11-02 | Pfizer Inc. | Compositions and methods for eliciting an immune response protective against lyme disease |
| WO2024050512A2 (en) * | 2022-09-02 | 2024-03-07 | The Medical College Of Wisconsin, Inc. | Use of immunogenic t cell epitopes for lyme disease vaccination and diagnosis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248562B1 (en) * | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| DK1311540T3 (da) | 2000-08-18 | 2008-04-28 | Brookhaven Sciences Ass Llc | Ændret OspA af Borrelia Burgdorferi |
| UA89481C2 (uk) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| EP2059526A2 (en) | 2006-09-15 | 2009-05-20 | Intercell AG | Borrelia antigens |
| PT2468300T (pt) | 2006-09-26 | 2018-01-30 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
| KR102222869B1 (ko) * | 2010-05-14 | 2021-03-04 | 박스알타 인코퍼레이티드 | 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법 |
| TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
| TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| ES2740985T3 (es) | 2014-01-09 | 2020-02-07 | Valneva Austria Gmbh | Fragmentos mutantes de OspA y métodos y usos relacionados con los mismos |
| CZ2014320A3 (cs) | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| ES2957939T3 (es) | 2017-04-13 | 2024-01-30 | Valneva Austria Gmbh | Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos |
-
2015
- 2015-01-09 ES ES15703228T patent/ES2740985T3/es active Active
- 2015-01-09 EA EA201691095A patent/EA034554B1/ru unknown
- 2015-01-09 NZ NZ721015A patent/NZ721015A/en unknown
- 2015-01-09 BR BR112016015678A patent/BR112016015678B1/pt active IP Right Grant
- 2015-01-09 WO PCT/EP2015/050365 patent/WO2015104396A1/en active Application Filing
- 2015-01-09 EP EP15703228.5A patent/EP3092246B1/en active Active
- 2015-01-09 RS RS20190970A patent/RS59075B1/sr unknown
- 2015-01-09 PL PL15703228T patent/PL3092246T3/pl unknown
- 2015-01-09 KR KR1020167015981A patent/KR102460165B1/ko active IP Right Grant
- 2015-01-09 PT PT15703228T patent/PT3092246T/pt unknown
- 2015-01-09 US US15/110,151 patent/US9975927B2/en active Active
- 2015-01-09 EP EP19177679.8A patent/EP3564257A1/en active Pending
- 2015-01-09 MX MX2016008989A patent/MX369195B/es active IP Right Grant
- 2015-01-09 BR BR122023024315-3A patent/BR122023024315A2/pt unknown
- 2015-01-09 TR TR2019/10117T patent/TR201910117T4/tr unknown
- 2015-01-09 JP JP2016541706A patent/JP6505110B2/ja active Active
- 2015-01-09 CN CN201580003319.2A patent/CN105980398B/zh active Active
- 2015-01-09 SI SI201530777T patent/SI3092246T1/sl unknown
- 2015-01-09 LT LTEP15703228.5T patent/LT3092246T/lt unknown
- 2015-01-09 DK DK15703228.5T patent/DK3092246T3/da active
- 2015-01-09 CA CA2931110A patent/CA2931110A1/en active Pending
- 2015-01-09 HU HUE15703228A patent/HUE043779T2/hu unknown
- 2015-01-09 AU AU2015205520A patent/AU2015205520B2/en active Active
-
2016
- 2016-04-19 ZA ZA2016/02690A patent/ZA201602690B/en unknown
-
2018
- 2018-04-04 US US15/944,835 patent/US10766931B2/en active Active
-
2019
- 2019-06-17 HR HRP20191086 patent/HRP20191086T1/hr unknown
- 2019-06-27 CY CY20191100676T patent/CY1121734T1/el unknown
-
2020
- 2020-08-11 US US16/990,023 patent/US11572392B2/en active Active
-
2023
- 2023-01-06 US US18/150,971 patent/US20230322869A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016015678A2 (pt) | Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso | |
| BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
| BR112017003194A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra. | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| BR112017003582A2 (pt) | anticorpos, composições e usos | |
| BR112017025564B8 (pt) | Anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
| BR112017015906A2 (pt) | complexo compreendendo um peptídeo de penetração celular, uma carga e um agonista de peptídeo tlr | |
| BR112018011073A2 (pt) | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| EA201590162A1 (ru) | МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ | |
| BR112016022814A8 (pt) | composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| BR112016013347A8 (pt) | anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos. | |
| BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
| BR112012005713A2 (pt) | vacinas direcionadas a célula langerhans. | |
| EP4324845A3 (en) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure | |
| BR112016015936A2 (pt) | Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição | |
| BR112019005129A2 (pt) | anticorpos anti-pd-1 | |
| EA201892774A1 (ru) | Антитела | |
| BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina | |
| EA201690503A1 (ru) | Антитела | |
| BR112016023915A2 (pt) | métodos de permissão de reação imunológica, de imunização de mamíferos e de tratamento ou prevenção de infecções, composições, peptídeo isolado, anticorpo, ácido nucleico isolado, construção genética e célula hospedeira | |
| BR112017027702A2 (pt) | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) | |
| BR112017001782A2 (pt) | fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023024315-3 PROTOCOLO 870230102267 EM 21/11/2023 16:09. |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/01/2015, OBSERVADAS AS CONDICOES LEGAIS |